Isivumelwano Esitsha Sokuqeshisa Ubomi: Unyango lwe-CD7 CAR-T oluphumeleleyo ludibanisa ukufakelwa kwezityalo kumntwana oneminyaka eli-15 ubudala one-T-ALL ephinde yabuyela umva
Kwiminyaka eli-15 kuphela ubudala, ubomi bomfana othile batshintshatshintsha ngenxa yokufunyaniswa kwakhe ene-T-cell acute lymphoblastic leukemia (T-ALL), eyayiphawulwa luthotho lweendlela zonyango ezinzima kunye neengxaki. Nangona wayefumana i-chemotherapy kunye nokufakelwa i-allogeneic stem cell, wajongana nokubuyela umva kwangoko kunye neengxaki. Nangona kunjalo, ngokuzinikela kosapho lwakhe kunye nolwazi lweqela lezonyango kwi-BIOOCUS, wafumana unyango lwe-CD7 CAR-T, ekugqibeleni lwakhokelela ekufakweni kwesibini okusindileyo ubomi.
Ekuqaleni uxilongwe ngoDisemba ka-2020, isigulana safumana ukuphumla ngokupheleleyo emva kokuthatha i-chemotherapy izihlandlo ezininzi. Nangona kunjalo, kwiinyanga ezintathu emva kokufakelwa isibeleko, saphinda sabuyela kwimeko yesiqhelo, okwabangelwa kukubandakanyeka kwenkqubo yemithambo-luvo ephakathi. Unyango oluqhelekileyo aluzange lusebenze, nto leyo eyashiya usapho lufuna ezinye iindlela.
Ngo-Okthobha ka-2021, isigulana sangeniswa kwi-BIOOCUS, apho safumana khona i-chemotherapy eyongezelelweyo ukunciphisa umthwalo wethumba ngaphambi kokuba sinyangwe ngeeseli ze-CD7 CAR-T. Ngelishwa, umzamo wokuqala we-CAR-T awuzange uphumelele, nto leyo eyabangela ukuba iqela lezonyango liqwalasele uvavanyo lweklinikhi oluqhubekayo lwe-CD7 universal CAR-T therapy.
Unyango lwe-Universal CAR-T lubonelela ngeenzuzo ezibalulekileyo, kubandakanya ukukwazi ukusebenzisa ii-T-cells ezivela kubanikeli abasempilweni, okuvumela ukufikelela ngokukhawuleza kunyango ngaphandle kwesidingo sokwenza ngokwezifiso ngokwezifiso. Oku kwakubalulekile kwisigulana, esasinomthwalo omkhulu wesimila kwaye sasingenako ukubonelela ngeeseli ezaneleyo kunyango lwendabuko lwe-CAR-T.
Ngomhla wesi-2 kweyoMnga ngo-2021, isigulana safumana iiseli ze-CD7 CAR-T. Emva konyango, ekuqaleni sajongana nemingeni, kuquka umkhuhlane kunye nokudinwa. Nangona kunjalo, ngoncedo oluxhaswayo, imeko yakhe yazinza, kwaye uvavanyo olulandelayo lwatyhila ukuchacha okumangalisayo, kungekho bungqina besifo esincinci esisele (MRD).
Emva kolu nyango luphumeleleyo, isigulana safakelwa utyando lwesibini, olwahamba kakuhle. Ngoku, phantse emva kweminyaka emithathu, siphilile, sibuyela kwimisebenzi yaso eqhelekileyo kwaye siyonwabela ubomi, nto leyo eyanceda usapho lwaso.
UGqr. Zhang Xian, intloko yesebe le-hematology kwi-BIOOCUS, ugxininisa ukubaluleka konyango lwe-CD7 universal CAR-T njengokhetho olubalulekileyo kwizigulana ezingakwaziyo ukufumana unyango lwendabuko. Eli tyala ligxininisa ikamva elithembisayo lonyango lwe-CAR-T ekunyangeni izigulana ze-T-cell, ingakumbi kwabo baneentlobo ze-leukemia eziphinde zabuya.
Njengoko uphando luqhubeka, amandla onyango lwe-CAR-T ayaqhubeka nokukhula, enika ithemba elitsha kwizigulana ezijongene neemeko ezinzima ezifana ne-T-ALL. I-BIOOCUS isazimisele ekuqaliseni unyango olutsha nokuphucula iziphumo zezigulana ngophando oluqhubekayo lwezonyango.
Ukuze ufumane ulwazi oluthe kratya malunga nonyango lwethu lwe-CAR-T kunye nendlela olunokukunceda ngayo wena okanye umntu omthandayo, nceda unxibelelane ne-BIOOCUS.